Plasma 9 ,11 -PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma
Open Access
- 1 June 2004
- Vol. 59 (6) , 459-464
- https://doi.org/10.1136/thx.2003.013573
Abstract
Background: Prostaglandin D2 (PGD2) is a major cyclooxygenase product generated by activated mast cells during an allergic response. Assessment of PGD2 and its metabolites in patients with asthma has mostly been performed in urine, bronchoalveolar lavage fluid and induced sputum, whereas human plasma determinations have been performed only sporadically. Methods: In 32 patients with allergic asthma and 50 healthy non-allergic controls, baseline plasma and urinary levels of 9α,11β-PGF2, a primary PGD2 metabolite, were assessed by gas chromatography/mass spectrometry. Serum tryptase levels were measured by fluoroenzyme immunoassay and urinary leukotriene E4 (LTE4) by ELISA. In a subgroup of 10 asthmatics (randomly selected from the 32 study patients) in whom bronchial allergen challenges with specific allergens (Dermatophagoides pteronyssinus, n = 4, mixed grass pollens, n = 6) were carried out, measurements were taken both before and after provocation. Results: At baseline no significant differences between mean plasma and urinary levels of the PGD2 metabolite and serum tryptase levels were found in asthmatics or controls. Asthmatic patients had significantly higher urinary LTE4 levels. Allergen challenge resulted in a significant early increase in the mean plasma 9α,11β-PGF2 level and only a borderline but significant increase in the urinary 9α,11β-PGF2 level within 2 hours after provocation. The challenge did not produce statistically significant changes in serum tryptase levels. Urinary LTE4 levels remained significantly increased 4 hours after provocation. Conclusions: PGD2 is actively involved in the early asthmatic response to allergens. Measurement of 9α,11β-PGF2 release into plasma rather than urine following allergen challenge is a sensitive marker of enhanced PGD2 synthesis, most probably due to mast cell activation.Keywords
This publication has 28 references indexed in Scilit:
- Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of PrematurityNew England Journal of Medicine, 2004
- Analyses of prostaglandin D2 metabolites in urine: comparison between enzyme immunoassay and negative ion chemical ionisation gas chromatography-mass spectrometryProstaglandins & Other Lipid Mediators, 1999
- Urinary excretion of inflammatory mediators during allergen‐induced early and late phase asthmatic reactionsClinical and Experimental Allergy, 1998
- An approach to the understanding of the nasal early‐phase reaction induced by nasal allergen challengeAllergy, 1997
- Increased urinary excretion of the prostaglandin D2 metabolite 9α,11β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstructionJournal of Allergy and Clinical Immunology, 1996
- Detection of the major urinary metabolite of prostaglandin D in the circulation: Demonstration of elevated levels in patients with disorders of systemic mast cell activationJournal of Allergy and Clinical Immunology, 1994
- Comparative vascular effects of histamine, prostaglandin (PG) D2 and its metabolite 9alpha, 11beta-PGF2 in human skinClinical and Experimental Allergy, 1988
- Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and MastocytosisNew England Journal of Medicine, 1987
- 9 alpha,11 beta-prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways.Journal of Clinical Investigation, 1987
- Release of Prostaglandin D2into Human Airways during Acute Antigen ChallengeNew England Journal of Medicine, 1986